DE69028684D1 - Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung

Info

Publication number
DE69028684D1
DE69028684D1 DE69028684T DE69028684T DE69028684D1 DE 69028684 D1 DE69028684 D1 DE 69028684D1 DE 69028684 T DE69028684 T DE 69028684T DE 69028684 T DE69028684 T DE 69028684T DE 69028684 D1 DE69028684 D1 DE 69028684D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
production
receptor beta
antibodies against
adhesion receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69028684T
Other languages
English (en)
Other versions
DE69028684T2 (de
Inventor
James Hildreth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69028684D1 publication Critical patent/DE69028684D1/de
Publication of DE69028684T2 publication Critical patent/DE69028684T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69028684T 1989-06-02 1990-05-30 Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung Expired - Fee Related DE69028684T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36127189A 1989-06-02 1989-06-02
PCT/US1990/002979 WO1990015076A2 (en) 1989-06-02 1990-05-30 MONOCLONAL ANTIBODIES AGAINST LEUKOCYTE ADHESION RECEPTOR β-CHAIN, METHODS OF PRODUCING THESE ANTIBODIES AND USE THEREFORE

Publications (2)

Publication Number Publication Date
DE69028684D1 true DE69028684D1 (de) 1996-10-31
DE69028684T2 DE69028684T2 (de) 1997-05-22

Family

ID=23421348

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69028684T Expired - Fee Related DE69028684T2 (de) 1989-06-02 1990-05-30 Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung

Country Status (10)

Country Link
US (4) US5888508A (de)
EP (1) EP0432249B1 (de)
JP (2) JP3048632B2 (de)
AT (1) ATE143376T1 (de)
AU (2) AU645016B2 (de)
CA (1) CA2033347C (de)
DE (1) DE69028684T2 (de)
DK (1) DK0432249T3 (de)
ES (1) ES2095876T3 (de)
WO (1) WO1990015076A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
DE69028684T2 (de) * 1989-06-02 1997-05-22 The Johns Hopkins University School Of Medicine, Baltimore, Md. Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5646251A (en) * 1993-11-05 1997-07-08 The Board Of Trustees Of Leeland Stanford Jr. Univ. Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
EP1163003B1 (de) 1999-03-19 2009-08-12 Genentech, Inc. Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
JP2003527439A (ja) 2000-03-17 2003-09-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗cd18抗体と抗ccr2抗体の混合物を用いる狭窄および再狭窄を抑制する方法
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2568570A1 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US8440264B2 (en) * 2006-12-15 2013-05-14 Ford Global Technologies, Llc Method for preparing a brazed surface for receiving a coating
CN102448494B (zh) 2009-02-13 2016-02-03 免疫医疗公司 具有胞内可裂解的键的免疫共轭物
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN106999517A (zh) 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
EP3029067A1 (de) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Verwendung von blockierenden Reagenzien zur Verringerung von unspezifischer T-Zellenaktivierung
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
USD1005917S1 (en) * 2021-11-04 2023-11-28 Thor Tech, Inc. Wheel

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
JPH01502879A (ja) * 1987-02-26 1989-10-05 ダナ ファーバー キャンサー インスティテュート Lfa―1のクローニング
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
EP0314863B1 (de) * 1987-11-02 1994-12-07 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
GB8726230D0 (en) * 1987-11-10 1987-12-16 Rosen H Antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
ES2077572T3 (es) * 1988-09-28 1995-12-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular, y sus ligandos de fijacion.
CA2000048A1 (en) * 1988-10-03 1990-04-03 Edward F. Plow Peptides and antibodies that inhibit integrin-ligand bindin g
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
DE69028684T2 (de) * 1989-06-02 1997-05-22 The Johns Hopkins University School Of Medicine, Baltimore, Md. Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
AU6299390A (en) * 1989-08-18 1991-04-03 American National Red Cross, The Fibulin
US6720141B1 (en) * 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis

Also Published As

Publication number Publication date
ATE143376T1 (de) 1996-10-15
CA2033347C (en) 2000-02-29
WO1990015076A3 (en) 1991-04-18
JP3288996B2 (ja) 2002-06-04
AU5035393A (en) 1994-02-17
US20050158315A1 (en) 2005-07-21
AU5847190A (en) 1991-01-07
WO1990015076A2 (en) 1990-12-13
EP0432249A1 (de) 1991-06-19
US6921533B2 (en) 2005-07-26
CA2033347A1 (en) 1990-12-03
DK0432249T3 (da) 1997-02-17
ES2095876T3 (es) 1997-03-01
DE69028684T2 (de) 1997-05-22
US5888508A (en) 1999-03-30
AU666977B2 (en) 1996-02-29
JPH04501365A (ja) 1992-03-12
JP3048632B2 (ja) 2000-06-05
US6187308B1 (en) 2001-02-13
EP0432249B1 (de) 1996-09-25
AU645016B2 (en) 1994-01-06
EP0432249A4 (en) 1992-01-02
JP2000136200A (ja) 2000-05-16
US7368109B2 (en) 2008-05-06
US20010014325A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
DE69028684D1 (de) Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
NL300142I2 (nl) Monoclonaal antilichaam tegen een cytotoxine, hybridoma cellijn, die dat uitdrukt en werkwijze voor de bereiding van het gezuiverde cytotoxine.
EP0618929A4 (de) Bispezifische heterodimere antikörper.
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
DE69024163D1 (de) Koinzidenzarbitrierung für durchflusszytometrie
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
AR240175A1 (es) Una linea celular producida por tecnica de hibridoma y un anticuerpo monoclonal derivado de la misma.
NO162179C (no) Monoklonale antistoffer for anvendelse in vitro.
DE3382673D1 (de) Hybridzellinien, die gegen treponema gerichtete monoklonale antikoerper produzieren.
DE69204823D1 (de) Verfahren für die bestimmung der antikörpersätze und die t-zellrezeptoren des immunologischen systems.
DK191989A (da) Tumor-associeret glycoproteinantigen, antistoffer mod antigenet samt hybridoma-cellelinie, der producerer antistofferne
DE3485733D1 (de) Spezifische antigene der cea(karzyno-embryonales-antigen)familie, spezifische antikoerper und verfahren zu ihrer verwendung.
DE68907735D1 (de) Genfragmente, die die variable region eines anti-hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.
DE3687487D1 (de) Monoklonaler antikoerper, spezifisch fuer ein pigmentationassoziiertes antigen.
FI862978A0 (fi) Onkofetaalisia spesifisiä monoklonaalisia vasta-aineita, menetelmä niiden valmistamiseksi ja niiden käyttö.
IE862325L (en) Monoclonal antibodies
AU7504691A (en) Monoclonal antibodies against pp4, processes for the preapration thereof and the use thereof
IL79950A0 (en) Anti-trichomonas vaginalis mono-trichomonas clonal antibodies inducing complement-dependent cytotoxicity,their use in immunotherapy and immunodiagnosis
IL92312A0 (en) Monoclonal antibody specifically recognizing n-glycolyl type gm2,hybridoma producing the antibody and method for preparing the hybridoma
AR243932A1 (es) Hibridoma, procedimiento para la preparacion, anticuerpo monoclonal, procedimiento para su preparacion y composicion para diagnostico de base a dicho anticuerpo.
EP0667395A4 (de) Monoklonale antikörper, anwendung und verfahren zur herstellung.
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
DE3581732D1 (de) Schwungrad und verfahren zu dessen herstelung.
DE68913793D1 (de) Ein von einem Human-Human-Hybridom abgeleiteter monoklonaler Antikörper und dessen Verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee